AXGN · Axogen, Inc.

Track AXGN — free

$48.73 +0.68 (+1.42%) At close · Aug 14

Market Cap

$2.62B

53.76M

Up next

Next earnings call

Oct 26, 2026 Est · unconfirmed · in 10 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Jul 29, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Ask ALVIS about this →

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 14.3 · calm Equity put/call 0.52

Technical

price trend

Strong Buy

50 / 200-day cross No cross

Price vs 200-day avg +37%

above

Price vs 50-day avg +13%

above

RSI (14) 66

neutral

MACD trend Positive

52-week position 97%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +22%

trailing

6-month return +38%

trailing

YTD return +49%

this year

Relative strength +24%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $43 › 200d $36 — 50d above 200d

Institutional flow Accumulating

+13% holders QoQ · +52 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

7.57% of float · ▼ -25.2% MoM · 3.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

250 holders — near 3-yr high, broad support

Squeeze score 61

elevated · 0–100

Fundamentals

Fair

Revenue growth +20%

Y/Y

Gross margin 74%

contracting

EPS growth −48%

Y/Y

Free cash flow $-2.9M

Balance sheet $14.6M

net debt

Quant / Vol

risk profile

Very High

Volatility 54%

annualized · 1-yr

Max drawdown −19%

past year

ATR 4.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Jul 29, 2026

Full-year revenue growth · full-year 2026 up to $279M

Full-year revenue growth · full-year 2026 at least 24%

Gross margin · full-year 2026 at least 73%

Prior guidance period ended · from the Earnings Call filed Mar 31, 2024

Revenue · full year 2024 $177M – $181M

Gross margin · full year 2024 76% – 79%

Net cash flow · cumulatively for the period from April 1 through year-end $0

Guided vs delivered · last 1 settled

Revenue full year 2024

guided $177M – $181M

guided $177M – $181M $187.34M Beat +4.7%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy

0 · 3 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+37% Bullish

Price vs 50-day avg

+13% Bullish

RSI (14)

66 Neutral

MACD trend

Positive Bullish

52-week position

97% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $43 › 200d $36 — 50d above 200d

Institutional flow Accumulating

+13% holders QoQ · +52 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

7.57% of float · ▼ -25.2% MoM · 3.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

250 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $15 Now $49 · 97% Range high $50

vs 200-day avg +37% vs 50-day avg +13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted EBITDA non-GAAP	8.4M	Q2 2026	—

Adjusted net income non-GAAP	$4.1M	first quarter 2026	—
Newly covered lives	19.8M	full-year 2025	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
AXGN Axogen, Inc. this stock	$2.62B	+48.9%	+20.2%	—	7.6%
ABT Abbott Laboratories	$193.78B	-11.2%	+5.7%	31.2	1.3%
SYK Stryker Corp	$130.11B	-3.5%	+11.2%	35.2	2.2%
MDT Medtronic plc	$116.83B	-5.0%	+8.4%	24.5	1.4%
BSX Boston Scientific Corp	$75.11B	-45.6%	+12.5%	21.0	1.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

250

% held: 97.8%
Net QoQ: +2.6M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

227

View

Short & Settlement

Short Interest Falling

Shares short

4.1M

Days to cover: 3.4d
Change: -1.4M sh

View

Short Volume

Short vol %

41%

As of: Aug 14, 2026

Short Total

View

Fails to Deliver

FTD shares

598

Value: $24.3K
As of: Jul 13, 2026

View

Off-Exchange

Off-exchange %

45.9%

Week of: Jul 6, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

Donna Shalala

Amount: $1.0K–$15.0K
Traded: Jun 24, 2019

View

Financials

Revenue (FY)

$225.2M

Net income (FY): $-15.7M
EPS diluted: $-0.34

View

Filings

SEC Filings

Latest

8-K

Filed: Jul 29, 2026
This year: 10

View

Proposed Sales

Value

$643.9K

Shares: 13.4K
Filed: Aug 11, 2026

View

Earnings & Events

Earnings Calls

Last call

Jul 29, 2026

View

Performance

	5D	20D	120D	MTD	YTD
AXGN	+5.0%	+22.3%	+37.7%	+15.5%	+48.9%
SPY	+0.4%	+4.5%	+13.8%	+3.9%	+13.9%
vs SPY	+4.6%	+17.8%	+24.0%	+11.5%	+35.0%

Key facts CIK 805928 CUSIP 05463X106 13F (30d) 244 filings 240 filers Visit website Investor relations

AXGN · Axogen, Inc.

Price & Indicators

Up next

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance